Benzinga··Bamboo WorksJacobio Pharma Eyes 2026 Profitability on AstraZeneca Deal and Cancer Drug Sales
Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.
AZNprofitabilitylicensing agreement